Replies to post #178280 on Avid Bioservices Inc (CDMO)

[volgoat]

MDSC's effecting human disease is an interesting theory, but no where near proven in human diseases.

If it ends up to be proven DG should receive the Nobel Prize.

Myeloid derived suppressor cells (MDSC) have been described as a heterogeneous cell population with potent immune suppressor function in mice. Limited data are available on MDSC in human diseases. Interpretation of these data is complicated by the fact that different markers have been used to analyze human MDSC subtypes in various clinical settings.

Outlook

MDSC have gained a lot of attention in recent years mainly in the tumor immunology community. However, based on the results from murine studies in non-tumor settings, human MDSC will need to be analyzed in more detail in non-cancer patients as well. One major hurdle remains the heterogeneity of the cells. The only possibility of overcoming this problem will be through a thorough phenotypical and functional analysis of all potential MDSC subsets in different clinical settings. Identification of better markers will facilitate these studies. More in-depth analysis of the interaction of MDSC with other cell types will help understand the biological function and, finally, the specific targeting of human MDSC and their subtypes will help the effect of immune-based therapies in cancer.


http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3478130/
cited 131 times

[biopharm]

Dmitry Gabrilovich : Peregrine Pharmaceuticals KOL :

Below is an excerpt from the annual report chronicling the role of translational medicine at The Wistar Institute and the projects of three key faculty members.

A PIONEERING PROGRAM IN TUMOR IMMUNOLOGY

June 11, 2014

In 2013, Wistar recruited internationally recognized immunologist Dmitry Gabrilovich, M.D., Ph.D., to lead a cutting-edge program of the Cancer Center in Translational Tumor Immunology.

“We have come to understand that the immune system is a critical element of tumor progression,” said Gabrilovich, who was named the Christopher M. Davis Professor at the Institute. “Our goal is to make the immune system an active focus of cancer research. We want to convert cancer into a manageable, chronic disease and give patients a better quality of life.”

Gabrilovich is developing a dual program: the first, to consider how to stimulate immune response and change the microenvironment (cells and tissues) that gives rise to tumors; the second, to combine immunotherapy with other therapies to create more effective treatment strategies.

“Immunotherapy is a complex area of biomedical research that requires a multifaceted approach to the study of science and disease,” said Gabrilovich.

“We’re building our team with accomplished scientists investigating different aspects of the regulation of the immune system,” Gabrilovich said. Over the next two years, he plans to recruit four new team members with the aim of assembling a world-class interdisciplinary team.

http://www.wistar.org/wistar-today/wistar-wire/2014-06-11/the-annual-report-translational-research